Catalyst Wire Dossier Catalyst Wire Dossier

Panitumumab (Zr-89 labeled)

panitumumab · Amgen
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Panitumumab (Zr-89 labeled), covering 2025-12-26 to 2025-12-26. Get the full timeline:

Most recent: Clinical Trial Update: Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma [EARLY_Phase 1]

See pricing